{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:50:13Z","timestamp":1780692613608,"version":"3.54.1"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T00:00:00Z","timestamp":1553212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0211600","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T17:27:01Z","timestamp":1553275621000},"page":"e0211600","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-4963","authenticated-orcid":true,"given":"Even H.","family":"Rustad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata D.","family":"Yellapantula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresia","family":"Akhlaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elli","family":"Papaemmanuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,3,22]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"O Landgren","year":"2016","journal-title":"Bone marrow transplantation"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"S Kumar","year":"2016","journal-title":"The lancet oncology"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis","volume":"3","author":"NC Munshi","year":"2017","journal-title":"JAMA oncology"},{"issue":"25","key":"ref4","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials","volume":"35","author":"JJ Lahuerta","year":"2017","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"ref5","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","author":"A Perrot","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"ref6","first-page":"435","article-title":"Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial.","volume":"130","author":"H Avet-Loiseau","year":"2017","journal-title":"Blood"},{"issue":"20","key":"ref7","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"J Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma","volume":"1","author":"N Korde","year":"2015","journal-title":"JAMA oncology"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"S Mailankody","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2018.02.011","article-title":"Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?","volume":"55","author":"M. Roshal","year":"2018","journal-title":"Semin Hematol"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"J Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"M Roshal","year":"2017","journal-title":"Blood advances"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2013-05-506170","article-title":"Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity","volume":"122","author":"A Flanders","year":"2013","journal-title":"Blood"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"E502","DOI":"10.1002\/ajh.24540","article-title":"Myeloma minimal residual disease testing in the United States: Evidence of improved standardization","volume":"91","author":"D Salem","year":"2016","journal-title":"Am J Hematol"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminhematol.2018.02.007","article-title":"Minimal residual disease detection of myeloma using sequencing of immunoglobulin heavy chain gene VDJ regions","volume":"55","author":"C Ho","year":"2018","journal-title":"Semin Hematol"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.seminhematol.2018.03.003","article-title":"MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool","volume":"55","author":"O. Landgren","year":"2018","journal-title":"Semin Hematol"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma","volume":"31","author":"J Martinez-Lopez","year":"2017","journal-title":"Leukemia"},{"key":"ref18","article-title":"Establishment of Immunoglobulin Heavy Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.","author":"ME Arcila","year":"2018","journal-title":"J Mol Diagn"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.","volume":"28","author":"H Takamatsu","year":"2017","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"M Ladetto","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"MV Mateos","year":"2018","journal-title":"The New England journal of medicine"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.1093\/nar\/gkt382","article-title":"IgBLAST: an immunoglobulin variable domain sequence analysis tool","volume":"41","author":"J Ye","year":"2013","journal-title":"Nucleic acids research"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology","volume":"17","author":"DT Cheng","year":"2015","journal-title":"The Journal of Molecular Diagnostics"},{"issue":"23","key":"ref24","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"E Papaemmanuil","year":"2016","journal-title":"The New England journal of medicine"},{"key":"ref25","article-title":"myTYPE targeted next generation sequencing assay for detection of IGH translocations and copy number alterations in multiple myeloma","author":"M Hultcrantz","year":"2018","journal-title":"European Hematology Association"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"SV Rajkumar","year":"2014","journal-title":"The lancet oncology"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1038\/bcj.2016.72","article-title":"A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.","volume":"6","author":"N Bolli","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref28","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","author":"N Bolli","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1365-2567.2004.01902.x","article-title":"Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma","volume":"112","author":"V Perfetti","year":"2004","journal-title":"Immunology"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"JJ van Dongen","year":"2003","journal-title":"Leukemia"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"D Gonzalez","year":"2007","journal-title":"Blood"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"AC Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jim.2016.12.006","article-title":"A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates","volume":"442","author":"JA Delgado","year":"2017","journal-title":"J Immunol Methods"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.leu.2402937","article-title":"Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR","volume":"17","author":"D Gonzalez","year":"2003","journal-title":"Leukemia"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15075","article-title":"Molecular detection of minimal residual disease in multiple myeloma","volume":"181","author":"Y Bai","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008","volume":"24","author":"M Bruggemann","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/blood.V97.4.1001","article-title":"Ordered recombination of immunoglobulin light chain genes occurs at the IGK locus but seems less strict at the IGL locus","volume":"97","author":"M van der Burg","year":"2001","journal-title":"Blood"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","article-title":"Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.","volume":"19","author":"DS Ross","year":"2017","journal-title":"J Mol Diagn"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"K Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"GM Frampton","year":"2013","journal-title":"Nature biotechnology"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12659","article-title":"Immunoglobulin gene analysis as a tool for investigating human immune responses","volume":"284","author":"D Dunn-Walters","year":"2018","journal-title":"Immunol Rev"},{"issue":"6","key":"ref42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bjh.14180","article-title":"ARTISAN PCR: rapid identification of full-length immunoglobulin rearrangements without primer binding bias","volume":"178","author":"MT Koning","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"ref43","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.","volume":"4","author":"D Kazandjian","year":"2018","journal-title":"JAMA oncology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0211600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T16:51:57Z","timestamp":1589043117000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0211600"}},"subtitle":[],"editor":[{"given":"Noel F. C. C.","family":"de Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,22]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0211600","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,22]]}}}